Post job

Synthetic Genomics CEO and executives

Executive Summary. Based on our data team's research, Oliver Fetzer is the Synthetic Genomics's CEO. Synthetic Genomics has 750 employees, of which 17 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Synthetic Genomics executive team is 29% female and 71% male.
  • 68% of the management team is White.
  • 11% of Synthetic Genomics management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Synthetic Genomics?
Share your experience

Rate Synthetic Genomics' leadership communication with employees.

Zippia waving zebra
Name & TitleBio
Oliver Fetzer

CEO

Oliver Fetzer's LinkedIn

Dr. Fetzer has served as CEO and Board Member of Synthetic Genomics since November 2014. Previously, Dr. Fetzer served as President and CEO of Cerulean Pharma Inc. for five years, a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served for five years in a variety of positions of increasing responsibility at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development. Dr. Fetzer began his career at the Boston Consulting Group (BCG), a global leading management consulting firm, where he advanced over nine years from Consultant to Project Leader, Principal, and ultimately Partner and Managing Director.

Craig Venter

Founder

Hamilton Smith

Co - Founder & Co - Chief Scientific Officer

Dr. Hamilton O. Smith co-founded Synthetic Genomics, Inc. in 2005 and serves as it's Co-Chief Scientific Officer. Dr. Smith serves as a Scientific Director of the Institute of Biological Energy Alternatives(IBEA) and Scientific Director of Synthetic Biology & Biological Energy Groups at the Venter Institute. He served as an Executive Vice President at Synthetic Genomics, Inc. He served as a Founder and Senior Director of DNA Resources of Celera Genomics and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Previously, Dr. Smith served as the head of faculty and professor of molecular biology and genetics of the Johns Hopkins University School of Medicine. He was a Co-Founder and collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria, and other bacteria. Dr. Smith is widely considered one of the experts in DNA library construction and DNA manipulation techniques. He serves as the Chairman and Member of Scientific Advisory Board of Metabolon Inc. Dr. Smith serves as a Member of Scientific Advisory Board at U.S. Genomics, Inc. and Excel Medical Ventures. He serves as a Director of Sunol Molecular Corporation. Dr. Smith was a Member of Scientific Advisory Board at Intercell Biomedical Research & Development AG until February 2006.

Doug Miller

Chief Financial Officer

Doug Miller is a Chief Financial Officer at Synthetic Genomics.

Margaret Dunbar

Vice President

Rob Brown

Vice President

About Jon

Jon Getzinger, Chief Sales and Marketing Officer, Genovia Bio Division

About Jon is a Jon Getzinger, Chief Sales and Marketing Officer, Genovia Bio Division at Synthetic Genomics. He works or has worked at Ocean Nutrition Canada. About attended University of Michigan.

Barry Schuler

Board Member

Bill McKee

Board Member

Fernanda Coelho

Chief Business Development Officer

Fernanda Coelho is a Chief Business Development Officer at Synthetic Genomics. She works or has worked at Accenture and BP.

Do you work at Synthetic Genomics?

Does the leadership team provide a clear direction for Synthetic Genomics?

Synthetic Genomics jobs

Synthetic Genomics founders

Name & TitleBio
Craig Venter

Founder

Hamilton Smith

Co - Founder & Co - Chief Scientific Officer

Dr. Hamilton O. Smith co-founded Synthetic Genomics, Inc. in 2005 and serves as it's Co-Chief Scientific Officer. Dr. Smith serves as a Scientific Director of the Institute of Biological Energy Alternatives(IBEA) and Scientific Director of Synthetic Biology & Biological Energy Groups at the Venter Institute. He served as an Executive Vice President at Synthetic Genomics, Inc. He served as a Founder and Senior Director of DNA Resources of Celera Genomics and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Previously, Dr. Smith served as the head of faculty and professor of molecular biology and genetics of the Johns Hopkins University School of Medicine. He was a Co-Founder and collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria, and other bacteria. Dr. Smith is widely considered one of the experts in DNA library construction and DNA manipulation techniques. He serves as the Chairman and Member of Scientific Advisory Board of Metabolon Inc. Dr. Smith serves as a Member of Scientific Advisory Board at U.S. Genomics, Inc. and Excel Medical Ventures. He serves as a Director of Sunol Molecular Corporation. Dr. Smith was a Member of Scientific Advisory Board at Intercell Biomedical Research & Development AG until February 2006.

Synthetic Genomics board members

Name & TitleBio
Oliver Fetzer

CEO

Oliver Fetzer's LinkedIn

Dr. Fetzer has served as CEO and Board Member of Synthetic Genomics since November 2014. Previously, Dr. Fetzer served as President and CEO of Cerulean Pharma Inc. for five years, a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served for five years in a variety of positions of increasing responsibility at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development. Dr. Fetzer began his career at the Boston Consulting Group (BCG), a global leading management consulting firm, where he advanced over nine years from Consultant to Project Leader, Principal, and ultimately Partner and Managing Director.

Barry Schuler

Board Member

Bill McKee

Board Member

Greg Lucier

Board Member

Reinhard Ambros

Board Member

Steve Jurvetson

Board Member

Tina Nova

Board Member

Synthetic Genomics executives FAQs

Zippia gives an in-depth look into the details of Synthetic Genomics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Synthetic Genomics. The employee data is based on information from people who have self-reported their past or current employments at Synthetic Genomics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Synthetic Genomics. The data presented on this page does not represent the view of Synthetic Genomics and its employees or that of Zippia.

Synthetic Genomics may also be known as or be related to SYNTHETIC GENOMICS INC, Synthetic Genomics, Synthetic Genomics Inc and Synthetic Genomics, Inc.